• 
  • New Child Indication
  • CDC ACIP Recommendations
  • Immunogenicity
  • Risk and Consequences
  • Safety
  • Patient Resources
  
• 
  
• 
  
• 
  • Disease Information
  • Is Your Adolescent at Risk?
  • Adolescent Immunization
    
    Schedule
  • Related Links
  • Important Safety Information
  
• 
  

Indication

Menactra vaccine is indicated for active immunization against invasive meningococcal disease caused by N meningitidis serogroups A, C, Y, and W-135 in persons 11 through 55 years of age. Menactra vaccine will not stimulate protection against infection caused by N meningitidis other than serogroups A, C, Y, and W-135.

Safety Information

There are risks associated with all vaccines. The most common local and systemic adverse reactions to Menactra vaccine include injection site pain, redness, and induration; headache, fatigue, and malaise. Other adverse reactions may occur. Menactra vaccine is contraindicated in persons with known hypersensitivity to any component of the vaccine or to latex, which is used in the vial stopper. Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of Menactra vaccine. Persons previously diagnosed with GBS should not receive Menactra vaccine. As with any vaccine, vaccination with Menactra vaccine may not protect 100% of individuals.

Before administering Menactra vaccine, please see full Prescribing Information.